Sp635
IMMUNISATION AND SUSCEPTIBILITY TO INFECTION IN PATIENTS WITH IBD
Date
May 7, 2023
Explore related products in the following collection:
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
PANEL DISCUSSION: LONG-TERM OUTCOMES AND COMPLICATIONS OF COVID IN IBD PATIENTS
The Cochrane Gut group supports the production of high quality and methodologically rigorous reviews for a portfolio that includes upper GI, IBD and functional bowel disease topics in adults and children…
PANEL DISCUSSION: REMOTE TELEHEALTH AND PATIENT EDUCATION TO SUPPORT POST COVID IBD CARE
The Cochrane Gut group supports the production of high quality and methodologically rigorous reviews for a portfolio that includes upper GI, IBD and functional bowel disease topics in adults and children…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…